Relexxii

Overview

methylphenidate

CNS stimulant

• gastric pH sensitive
• hypertensive effects
• lowers seizure threshold
• serotonergic effects
• tachycardia

• add MAO inhibitor to Interaction Check if recent (14 days) use

Contraindicated

• benzphetamine
Relexxii (methylphenidate)

+

benzphetamine

1 interaction

Contraindicated

methylphenidate + benzphetamine

contraindicated: combo may incr. risk of tachycardia, HTN, other cardiovascular and CNS stimulatory effects (additive effects, duplicate tx)

• isocarboxazid
Relexxii (methylphenidate)

+

isocarboxazid

1 interaction

Contraindicated

methylphenidate + isocarboxazid

contraindicated w/in 14 days of isocarboxazid use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• linezolid
Relexxii (methylphenidate)

+

linezolid

1 interaction

Contraindicated

methylphenidate + linezolid

contraindicated w/in 14 days of linezolid use; hold methylphenidate if urgent use; monitor BP, serotonin syndrome sx x2wk after methylphenidate D/C or 24h after last linezolid dose: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects, linezolid reversibly inhibits monoamine oxidase)

• methylene blue injection
Relexxii (methylphenidate)

+

methylene blue injection

1 interaction

Contraindicated

methylphenidate + methylene blue injection

contraindicated w/in 14 days of methylene blue use; hold methylphenidate if emergency use; monitor BP, serotonin syndrome sx up to 4h after last methylene blue dose; may resume methylphenidate 72h after last methylene blue dose: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects, methylene blue reversibly inhibits monoamine oxidase)

• phendimetrazine
Relexxii (methylphenidate)

+

phendimetrazine

1 interaction

Contraindicated

methylphenidate + phendimetrazine

contraindicated: combo may incr. risk of tachycardia, HTN (additive effects)

• phenelzine
Relexxii (methylphenidate)

+

phenelzine

1 interaction

Contraindicated

methylphenidate + phenelzine

contraindicated w/in 14 days of phenelzine use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• rasagiline
Relexxii (methylphenidate)

+

rasagiline

1 interaction

Contraindicated

methylphenidate + rasagiline

contraindicated w/in 14 days of rasagiline use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• safinamide
Relexxii (methylphenidate)

+

safinamide

1 interaction

Contraindicated

methylphenidate + safinamide

contraindicated w/in 14 days of safinamide use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• selegiline
Relexxii (methylphenidate)

+

selegiline

1 interaction

Contraindicated

methylphenidate + selegiline

contraindicated w/in 14 days of selegiline use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• selegiline transdermal
Relexxii (methylphenidate)

+

selegiline transdermal

1 interaction

Contraindicated

methylphenidate + selegiline transdermal

contraindicated w/in 14 days of selegiline use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• tranylcypromine
Relexxii (methylphenidate)

+

tranylcypromine

1 interaction

Contraindicated

methylphenidate + tranylcypromine

contraindicated w/in 14 days of tranylcypromine use: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects)

• yohimbe
Relexxii (methylphenidate)

+

yohimbe

1 interaction

Contraindicated

methylphenidate + yohimbe

contraindicated w/in 14 days of yohimbe use: combo may incr. risk of serotonin syndrome, HTN (incl. hypertensive crisis), tachycardia (additive effects, yohimbe inhibits monoamine oxidase)

Avoid/Use Alternative

• albuterol
Relexxii (methylphenidate)

+

albuterol

1 interaction

Avoid/Use Alternative

methylphenidate + albuterol

use alternative or monitor BP, HR w/ oral albuterol; risk may be lower w/ inhaled albuterol: combo may incr. risk of HTN, tachycardia (additive effects)

• aldesleukin
Relexxii (methylphenidate)

+

aldesleukin

1 interaction

Avoid/Use Alternative

methylphenidate + aldesleukin

avoid combo: combo may incr. risk of seizures (additive effects)

• alfentanil
Relexxii (methylphenidate)

+

alfentanil

1 interaction

Avoid/Use Alternative

methylphenidate + alfentanil

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• aluminum hydroxide
Relexxii (methylphenidate)

+

aluminum hydroxide

1 interaction

Avoid/Use Alternative

methylphenidate + aluminum hydroxide

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• amifampridine
Relexxii (methylphenidate)

+

amifampridine

1 interaction

Avoid/Use Alternative

methylphenidate + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• amphetamine
Relexxii (methylphenidate)

+

amphetamine

1 interaction

Avoid/Use Alternative

methylphenidate + amphetamine

consider alternative or decr. amphetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia, other adverse effects (additive effects, duplicate tx)

• buprenorphine
Relexxii (methylphenidate)

+

buprenorphine

1 interaction

Avoid/Use Alternative

methylphenidate + buprenorphine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• butorphanol
Relexxii (methylphenidate)

+

butorphanol

1 interaction

Avoid/Use Alternative

methylphenidate + butorphanol

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• calcium carbonate
Relexxii (methylphenidate)

+

calcium carbonate

1 interaction

Avoid/Use Alternative

methylphenidate + calcium carbonate

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• cimetidine
Relexxii (methylphenidate)

+

cimetidine

1 interaction

Avoid/Use Alternative

methylphenidate + cimetidine

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• citalopram
Relexxii (methylphenidate)

+

citalopram

1 interaction

Avoid/Use Alternative

methylphenidate + citalopram

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. citalopram levels, risk of serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• clomipramine
Relexxii (methylphenidate)

+

clomipramine

1 interaction

Avoid/Use Alternative

methylphenidate + clomipramine

use alternative or monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. clomipramine levels, risk of HTN, tachycardia, seizures, CNS stimulatory effects, serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• codeine
Relexxii (methylphenidate)

+

codeine

1 interaction

Avoid/Use Alternative

methylphenidate + codeine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• cyclobenzaprine
Relexxii (methylphenidate)

+

cyclobenzaprine

1 interaction

Avoid/Use Alternative

methylphenidate + cyclobenzaprine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• desipramine
Relexxii (methylphenidate)

+

desipramine

1 interaction

Avoid/Use Alternative

methylphenidate + desipramine

use alternative or monitor BP, HR, ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, CNS stimulatory effects, serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• desvenlafaxine
Relexxii (methylphenidate)

+

desvenlafaxine

1 interaction

Avoid/Use Alternative

methylphenidate + desvenlafaxine

use alternative or monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, serotonin syndrome (additive effects)

• dexlansoprazole
Relexxii (methylphenidate)

+

dexlansoprazole

1 interaction

Avoid/Use Alternative

methylphenidate + dexlansoprazole

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• dexmethylphenidate
Relexxii (methylphenidate)

+

dexmethylphenidate

1 interaction

Avoid/Use Alternative

methylphenidate + dexmethylphenidate

consider alternative or monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia, other adverse effects (additive effects, duplicate tx)

• dextroamphetamine
Relexxii (methylphenidate)

+

dextroamphetamine

1 interaction

Avoid/Use Alternative

methylphenidate + dextroamphetamine

consider alternative or decr. dextroamphetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia, other adverse effects (additive effects, duplicate tx)

• dihydrocodeine
Relexxii (methylphenidate)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

methylphenidate + dihydrocodeine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• dronabinol
Relexxii (methylphenidate)

+

dronabinol

1 interaction

Avoid/Use Alternative

methylphenidate + dronabinol

avoid combo: combo may incr. risk of HTN, tachycardia (additive effects)

• duloxetine
Relexxii (methylphenidate)

+

duloxetine

1 interaction

Avoid/Use Alternative

methylphenidate + duloxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• ephedra
Relexxii (methylphenidate)

+

ephedra

1 interaction

Avoid/Use Alternative

methylphenidate + ephedra

avoid combo: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• epinephrine inhaled
Relexxii (methylphenidate)

+

epinephrine inhaled

1 interaction

Avoid/Use Alternative

methylphenidate + epinephrine inhaled

avoid combo: combo may incr. risk of tachycardia, HTN, incl. hypertensive crisis (additive effects)

• escitalopram
Relexxii (methylphenidate)

+

escitalopram

1 interaction

Avoid/Use Alternative

methylphenidate + escitalopram

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. escitalopram levels, risk of serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• esomeprazole
Relexxii (methylphenidate)

+

esomeprazole

1 interaction

Avoid/Use Alternative

methylphenidate + esomeprazole

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• ethanol
Relexxii (methylphenidate)

+

ethanol

1 interaction

Avoid/Use Alternative

methylphenidate + ethanol

avoid combo w/ ER methylphenidate formulations (incl. cap, chewable, oral suspension, ODT); methylphenidate ER tab and IR methylphenidate formulations OK: combo may incr. methylphenidate levels, risk of adverse effects (alcohol causes more rapid release of methylphenidate dose)

• famotidine
Relexxii (methylphenidate)

+

famotidine

1 interaction

Avoid/Use Alternative

methylphenidate + famotidine

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• fentanyl
Relexxii (methylphenidate)

+

fentanyl

1 interaction

Avoid/Use Alternative

methylphenidate + fentanyl

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• fluoxetine
Relexxii (methylphenidate)

+

fluoxetine

1 interaction

Avoid/Use Alternative

methylphenidate + fluoxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. fluoxetine levels, risk of serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• fluvoxamine
Relexxii (methylphenidate)

+

fluvoxamine

1 interaction

Avoid/Use Alternative

methylphenidate + fluvoxamine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. fluvoxamine levels, risk of serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• furosemide
Relexxii (methylphenidate)

+

furosemide

1 interaction

Avoid/Use Alternative

methylphenidate + furosemide

use alternative or monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• gepirone
Relexxii (methylphenidate)

+

gepirone

1 interaction

Avoid/Use Alternative

methylphenidate + gepirone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• granisetron
Relexxii (methylphenidate)

+

granisetron

1 interaction

Avoid/Use Alternative

methylphenidate + granisetron

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• hydrocodone
Relexxii (methylphenidate)

+

hydrocodone

1 interaction

Avoid/Use Alternative

methylphenidate + hydrocodone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• hydromorphone
Relexxii (methylphenidate)

+

hydromorphone

1 interaction

Avoid/Use Alternative

methylphenidate + hydromorphone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• imipramine
Relexxii (methylphenidate)

+

imipramine

1 interaction

Avoid/Use Alternative

methylphenidate + imipramine

use alternative or monitor imipramine levels, BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. imipramine levels, risk of HTN, tachycardia, CNS stimulatory effects, serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• isoniazid
Relexxii (methylphenidate)

+

isoniazid

1 interaction

Avoid/Use Alternative

methylphenidate + isoniazid

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, isoniazid inhibits monoamine oxidase)

• landiolol
Relexxii (methylphenidate)

+

landiolol

1 interaction

Avoid/Use Alternative

methylphenidate + landiolol

use alternative or monitor HR, BP: combo may decr. landiolol efficacy (antagonistic effects)

• lansoprazole
Relexxii (methylphenidate)

+

lansoprazole

1 interaction

Avoid/Use Alternative

methylphenidate + lansoprazole

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• levomilnacipran
Relexxii (methylphenidate)

+

levomilnacipran

1 interaction

Avoid/Use Alternative

methylphenidate + levomilnacipran

use alternative or monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• levorphanol
Relexxii (methylphenidate)

+

levorphanol

1 interaction

Avoid/Use Alternative

methylphenidate + levorphanol

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• lisdexamfetamine
Relexxii (methylphenidate)

+

lisdexamfetamine

1 interaction

Avoid/Use Alternative

methylphenidate + lisdexamfetamine

consider alternative or decr. lisdexamfetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia, other adverse effects (additive effects, duplicate tx)

• lithium
Relexxii (methylphenidate)

+

lithium

1 interaction

Avoid/Use Alternative

methylphenidate + lithium

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• magnesium carbonate
Relexxii (methylphenidate)

+

magnesium carbonate

1 interaction

Avoid/Use Alternative

methylphenidate + magnesium carbonate

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• magnesium hydroxide
Relexxii (methylphenidate)

+

magnesium hydroxide

1 interaction

Avoid/Use Alternative

methylphenidate + magnesium hydroxide

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• magnesium oxide
Relexxii (methylphenidate)

+

magnesium oxide

1 interaction

Avoid/Use Alternative

methylphenidate + magnesium oxide

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• meperidine
Relexxii (methylphenidate)

+

meperidine

1 interaction

Avoid/Use Alternative

methylphenidate + meperidine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• metaxalone
Relexxii (methylphenidate)

+

metaxalone

1 interaction

Avoid/Use Alternative

methylphenidate + metaxalone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• methadone
Relexxii (methylphenidate)

+

methadone

1 interaction

Avoid/Use Alternative

methylphenidate + methadone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• methamphetamine
Relexxii (methylphenidate)

+

methamphetamine

1 interaction

Avoid/Use Alternative

methylphenidate + methamphetamine

consider alternative or decr. methamphetamine start dose; monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, tachycardia, serotonin syndrome (additive effects, duplicate tx)

• methylene blue oral
Relexxii (methylphenidate)

+

methylene blue oral

1 interaction

Avoid/Use Alternative

methylphenidate + methylene blue oral

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects, methylene blue reversibly inhibits monoamine oxidase)

• midodrine
Relexxii (methylphenidate)

+

midodrine

1 interaction

Avoid/Use Alternative

methylphenidate + midodrine

use alternative or monitor BP: combo may incr. risk of HTN (additive effects)

• milnacipran
Relexxii (methylphenidate)

+

milnacipran

1 interaction

Avoid/Use Alternative

methylphenidate + milnacipran

use alternative or monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, tachycardia (additive effects)

• mirtazapine
Relexxii (methylphenidate)

+

mirtazapine

1 interaction

Avoid/Use Alternative

methylphenidate + mirtazapine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• morphine
Relexxii (methylphenidate)

+

morphine

1 interaction

Avoid/Use Alternative

methylphenidate + morphine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• nalbuphine
Relexxii (methylphenidate)

+

nalbuphine

1 interaction

Avoid/Use Alternative

methylphenidate + nalbuphine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• nizatidine
Relexxii (methylphenidate)

+

nizatidine

1 interaction

Avoid/Use Alternative

methylphenidate + nizatidine

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• nortriptyline
Relexxii (methylphenidate)

+

nortriptyline

1 interaction

Avoid/Use Alternative

methylphenidate + nortriptyline

use alternative or monitor nortriptyline levels, BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. nortriptyline levels, risk of HTN, tachycardia, CNS simulatory effects, serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• oliceridine
Relexxii (methylphenidate)

+

oliceridine

1 interaction

Avoid/Use Alternative

methylphenidate + oliceridine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• omeprazole
Relexxii (methylphenidate)

+

omeprazole

1 interaction

Avoid/Use Alternative

methylphenidate + omeprazole

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• ondansetron
Relexxii (methylphenidate)

+

ondansetron

1 interaction

Avoid/Use Alternative

methylphenidate + ondansetron

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• opium
Relexxii (methylphenidate)

+

opium

1 interaction

Avoid/Use Alternative

methylphenidate + opium

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• oxycodone
Relexxii (methylphenidate)

+

oxycodone

1 interaction

Avoid/Use Alternative

methylphenidate + oxycodone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• oxymorphone
Relexxii (methylphenidate)

+

oxymorphone

1 interaction

Avoid/Use Alternative

methylphenidate + oxymorphone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• pantoprazole
Relexxii (methylphenidate)

+

pantoprazole

1 interaction

Avoid/Use Alternative

methylphenidate + pantoprazole

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• paroxetine
Relexxii (methylphenidate)

+

paroxetine

1 interaction

Avoid/Use Alternative

methylphenidate + paroxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. paroxetine levels, risk of serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• pentazocine
Relexxii (methylphenidate)

+

pentazocine

1 interaction

Avoid/Use Alternative

methylphenidate + pentazocine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• procarbazine
Relexxii (methylphenidate)

+

procarbazine

1 interaction

Avoid/Use Alternative

methylphenidate + procarbazine

use alternative or monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN, incl. hypertensive crisis (additive effects, procarbazine inhibits monoamine oxidase)

• rabeprazole
Relexxii (methylphenidate)

+

rabeprazole

1 interaction

Avoid/Use Alternative

methylphenidate + rabeprazole

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• remifentanil
Relexxii (methylphenidate)

+

remifentanil

1 interaction

Avoid/Use Alternative

methylphenidate + remifentanil

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• sertraline
Relexxii (methylphenidate)

+

sertraline

1 interaction

Avoid/Use Alternative

methylphenidate + sertraline

use alternative or monitor serotonin syndrome sx, especially during initiation/titration; consider ECG monitoring and decr. sertraline dose if clinically warranted: combo may incr. sertraline levels, risk of serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• sodium bicarbonate
Relexxii (methylphenidate)

+

sodium bicarbonate

1 interaction

Avoid/Use Alternative

methylphenidate + sodium bicarbonate

consider alternative w/ some oral methylphenidate ER formulations and oral sodium bicarbonate: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• sodium citrate
Relexxii (methylphenidate)

+

sodium citrate

1 interaction

Avoid/Use Alternative

methylphenidate + sodium citrate

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• sodium zirconium cyclosilicate
Relexxii (methylphenidate)

+

sodium zirconium cyclosilicate

1 interaction

Avoid/Use Alternative

methylphenidate + sodium zirconium cyclosilicate

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• sufentanil
Relexxii (methylphenidate)

+

sufentanil

1 interaction

Avoid/Use Alternative

methylphenidate + sufentanil

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• tapentadol
Relexxii (methylphenidate)

+

tapentadol

1 interaction

Avoid/Use Alternative

methylphenidate + tapentadol

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• tipranavir
Relexxii (methylphenidate)

+

tipranavir

1 interaction

Avoid/Use Alternative

methylphenidate + tipranavir

avoid combo w/ ER methylphenidate formulations (incl. cap, chewable, oral suspension, ODT); methylphenidate ER tab and IR methylphenidate formulations OK: combo may incr. methylphenidate levels, risk of adverse effects (tipranavir capsules contain alcohol, alcohol causes more rapid release of methylphenidate dose)

• tramadol
Relexxii (methylphenidate)

+

tramadol

1 interaction

Avoid/Use Alternative

methylphenidate + tramadol

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, seizures (additive effects)

• trimipramine
Relexxii (methylphenidate)

+

trimipramine

1 interaction

Avoid/Use Alternative

methylphenidate + trimipramine

use alternative or monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. trimipramine levels, risk of HTN, tachycardia, serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• venlafaxine
Relexxii (methylphenidate)

+

venlafaxine

1 interaction

Avoid/Use Alternative

methylphenidate + venlafaxine

use alternative or monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• vilazodone
Relexxii (methylphenidate)

+

vilazodone

1 interaction

Avoid/Use Alternative

methylphenidate + vilazodone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• vonoprazan
Relexxii (methylphenidate)

+

vonoprazan

1 interaction

Avoid/Use Alternative

methylphenidate + vonoprazan

consider alternative w/ some oral methylphenidate ER formulations: combo may alter methylphenidate release, incr. risk of adverse effects or decr. efficacy (altered dissolution of ER methylphenidate at higher gastric pH)

• vortioxetine
Relexxii (methylphenidate)

+

vortioxetine

1 interaction

Avoid/Use Alternative

methylphenidate + vortioxetine

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• ziprasidone
Relexxii (methylphenidate)

+

ziprasidone

1 interaction

Avoid/Use Alternative

methylphenidate + ziprasidone

use alternative or monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

Monitor/Modify Tx

• 5-HTP
Relexxii (methylphenidate)

+

5-HTP

1 interaction

Monitor/Modify Tx

methylphenidate + 5-HTP

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• abiraterone acetate
Relexxii (methylphenidate)

+

abiraterone acetate

1 interaction

Monitor/Modify Tx

methylphenidate + abiraterone acetate

monitor BP: combo may incr. risk of HTN (additive effects)

• acebutolol
Relexxii (methylphenidate)

+

acebutolol

1 interaction

Monitor/Modify Tx

methylphenidate + acebutolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• albuterol inhaled
Relexxii (methylphenidate)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

methylphenidate + albuterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• aliskiren
Relexxii (methylphenidate)

+

aliskiren

1 interaction

Monitor/Modify Tx

methylphenidate + aliskiren

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• almotriptan
Relexxii (methylphenidate)

+

almotriptan

1 interaction

Monitor/Modify Tx

methylphenidate + almotriptan

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, serotonin syndrome (additive effects)

• amiloride
Relexxii (methylphenidate)

+

amiloride

1 interaction

Monitor/Modify Tx

methylphenidate + amiloride

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• amitriptyline
Relexxii (methylphenidate)

+

amitriptyline

1 interaction

Monitor/Modify Tx

methylphenidate + amitriptyline

monitor BP, HR, ECG, serotonin syndrome sx, especially during initiation/titration: combo may incr. amitriptyline levels, risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• amlodipine
Relexxii (methylphenidate)

+

amlodipine

1 interaction

Monitor/Modify Tx

methylphenidate + amlodipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• amoxapine
Relexxii (methylphenidate)

+

amoxapine

1 interaction

Monitor/Modify Tx

methylphenidate + amoxapine

monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. amoxapine levels, risk of HTN, tachycardia, serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• angiotensin II
Relexxii (methylphenidate)

+

angiotensin II

1 interaction

Monitor/Modify Tx

methylphenidate + angiotensin II

monitor BP: combo may incr. risk of HTN (additive effects)

• aprocitentan
Relexxii (methylphenidate)

+

aprocitentan

1 interaction

Monitor/Modify Tx

methylphenidate + aprocitentan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• arformoterol inhaled
Relexxii (methylphenidate)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

methylphenidate + arformoterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• armodafinil
Relexxii (methylphenidate)

+

armodafinil

1 interaction

Monitor/Modify Tx

methylphenidate + armodafinil

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• asciminib
Relexxii (methylphenidate)

+

asciminib

1 interaction

Monitor/Modify Tx

methylphenidate + asciminib

monitor BP: combo may incr. risk of HTN (additive effects)

• atenolol
Relexxii (methylphenidate)

+

atenolol

1 interaction

Monitor/Modify Tx

methylphenidate + atenolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• atropine
Relexxii (methylphenidate)

+

atropine

1 interaction

Monitor/Modify Tx

methylphenidate + atropine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• atropine ophthalmic
Relexxii (methylphenidate)

+

atropine ophthalmic

1 interaction

Monitor/Modify Tx

methylphenidate + atropine ophthalmic

monitor BP: combo may incr. risk of HTN (additive effects)

• axitinib
Relexxii (methylphenidate)

+

axitinib

1 interaction

Monitor/Modify Tx

methylphenidate + axitinib

monitor BP: combo may incr. risk of HTN (additive effects)

• azilsartan medoxomil
Relexxii (methylphenidate)

+

azilsartan medoxomil

1 interaction

Monitor/Modify Tx

methylphenidate + azilsartan medoxomil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• benazepril
Relexxii (methylphenidate)

+

benazepril

1 interaction

Monitor/Modify Tx

methylphenidate + benazepril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• benztropine
Relexxii (methylphenidate)

+

benztropine

1 interaction

Monitor/Modify Tx

methylphenidate + benztropine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• betamethasone
Relexxii (methylphenidate)

+

betamethasone

1 interaction

Monitor/Modify Tx

methylphenidate + betamethasone

monitor BP: combo may incr. risk of HTN (additive effects)

• betaxolol
Relexxii (methylphenidate)

+

betaxolol

1 interaction

Monitor/Modify Tx

methylphenidate + betaxolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• bevacizumab
Relexxii (methylphenidate)

+

bevacizumab

1 interaction

Monitor/Modify Tx

methylphenidate + bevacizumab

monitor BP: combo may incr. risk of HTN (additive effects)

• bismuth subsalicylate
Relexxii (methylphenidate)

+

bismuth subsalicylate

1 interaction

Monitor/Modify Tx

methylphenidate + bismuth subsalicylate

monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

• bisoprolol
Relexxii (methylphenidate)

+

bisoprolol

1 interaction

Monitor/Modify Tx

methylphenidate + bisoprolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• brigatinib
Relexxii (methylphenidate)

+

brigatinib

1 interaction

Monitor/Modify Tx

methylphenidate + brigatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• bromocriptine
Relexxii (methylphenidate)

+

bromocriptine

1 interaction

Monitor/Modify Tx

methylphenidate + bromocriptine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• budesonide
Relexxii (methylphenidate)

+

budesonide

1 interaction

Monitor/Modify Tx

methylphenidate + budesonide

monitor BP: combo may incr. risk of HTN (additive effects)

• bumetanide
Relexxii (methylphenidate)

+

bumetanide

1 interaction

Monitor/Modify Tx

methylphenidate + bumetanide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• bupropion
Relexxii (methylphenidate)

+

bupropion

1 interaction

Monitor/Modify Tx

methylphenidate + bupropion

monitor BP; consider lower bupropion doses: combo may incr. risk of HTN, seizures (additive effects)

• buspirone
Relexxii (methylphenidate)

+

buspirone

1 interaction

Monitor/Modify Tx

methylphenidate + buspirone

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• cabozantinib
Relexxii (methylphenidate)

+

cabozantinib

1 interaction

Monitor/Modify Tx

methylphenidate + cabozantinib

monitor BP: combo may incr. risk of HTN (additive effects)

• caffeine
Relexxii (methylphenidate)

+

caffeine

1 interaction

Monitor/Modify Tx

methylphenidate + caffeine

monitor BP, HR; avoid excessive caffeine intake: combo may incr. risk of HTN, tachycardia, CNS stimulatory effects (additive effects)

• caffeine citrate
Relexxii (methylphenidate)

+

caffeine citrate

1 interaction

Monitor/Modify Tx

methylphenidate + caffeine citrate

monitor BP, HR: combo may incr. risk of HTN, tachycardia, CNS stimulatory effects (additive effects)

• candesartan cilexetil
Relexxii (methylphenidate)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

methylphenidate + candesartan cilexetil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• cannabis
Relexxii (methylphenidate)

+

cannabis

1 interaction

Monitor/Modify Tx

methylphenidate + cannabis

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• captopril
Relexxii (methylphenidate)

+

captopril

1 interaction

Monitor/Modify Tx

methylphenidate + captopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• carbamazepine
Relexxii (methylphenidate)

+

carbamazepine

1 interaction

Monitor/Modify Tx

methylphenidate + carbamazepine

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome; may alter seizure control (additive effects; antagonistic effects, methylphenidate may decr. seizure threshold)

• carfilzomib
Relexxii (methylphenidate)

+

carfilzomib

1 interaction

Monitor/Modify Tx

methylphenidate + carfilzomib

monitor BP: combo may incr. risk of HTN (additive effects)

• carvedilol
Relexxii (methylphenidate)

+

carvedilol

1 interaction

Monitor/Modify Tx

methylphenidate + carvedilol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• celecoxib
Relexxii (methylphenidate)

+

celecoxib

1 interaction

Monitor/Modify Tx

methylphenidate + celecoxib

monitor BP: combo may incr. risk of HTN (additive effects)

• chlorothiazide
Relexxii (methylphenidate)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

methylphenidate + chlorothiazide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• chlorthalidone
Relexxii (methylphenidate)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

methylphenidate + chlorthalidone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• clevidipine
Relexxii (methylphenidate)

+

clevidipine

1 interaction

Monitor/Modify Tx

methylphenidate + clevidipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• clonidine
Relexxii (methylphenidate)

+

clonidine

1 interaction

Monitor/Modify Tx

methylphenidate + clonidine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• cocaine
Relexxii (methylphenidate)

+

cocaine

1 interaction

Monitor/Modify Tx

methylphenidate + cocaine

monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, tachycardia, serotonin syndrome, seizures (additive effects)

• copanlisib
Relexxii (methylphenidate)

+

copanlisib

1 interaction

Monitor/Modify Tx

methylphenidate + copanlisib

monitor BP: combo may incr. risk of HTN (additive effects, copanlisib may cause infusion-related HTN)

• corticotropin
Relexxii (methylphenidate)

+

corticotropin

1 interaction

Monitor/Modify Tx

methylphenidate + corticotropin

monitor BP: combo may incr. risk of HTN (additive effects)

• cortisone
Relexxii (methylphenidate)

+

cortisone

1 interaction

Monitor/Modify Tx

methylphenidate + cortisone

monitor BP: combo may incr. risk of HTN (additive effects)

• cyclosporine
Relexxii (methylphenidate)

+

cyclosporine

1 interaction

Monitor/Modify Tx

methylphenidate + cyclosporine

monitor BP: combo may incr. risk of HTN (additive effects)

• danazol
Relexxii (methylphenidate)

+

danazol

1 interaction

Monitor/Modify Tx

methylphenidate + danazol

monitor BP: combo may incr. risk of HTN (additive effects)

• darbepoetin alfa
Relexxii (methylphenidate)

+

darbepoetin alfa

1 interaction

Monitor/Modify Tx

methylphenidate + darbepoetin alfa

monitor BP: combo may incr. risk of HTN (additive effects)

• deflazacort
Relexxii (methylphenidate)

+

deflazacort

1 interaction

Monitor/Modify Tx

methylphenidate + deflazacort

monitor BP: combo may incr. risk of HTN (additive effects)

• desflurane
Relexxii (methylphenidate)

+

desflurane

1 interaction

Monitor/Modify Tx

methylphenidate + desflurane

D/C methylphenidate day of surgery: combo may incr. risk of intraoperative HTN, tachycardia (mechanism unknown)

• desmopressin
Relexxii (methylphenidate)

+

desmopressin

1 interaction

Monitor/Modify Tx

methylphenidate + desmopressin

monitor BP: combo may incr. risk of HTN (additive effects)

• dexamethasone
Relexxii (methylphenidate)

+

dexamethasone

1 interaction

Monitor/Modify Tx

methylphenidate + dexamethasone

monitor BP: combo may incr. risk of HTN (additive effects)

• dextromethorphan
Relexxii (methylphenidate)

+

dextromethorphan

1 interaction

Monitor/Modify Tx

methylphenidate + dextromethorphan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• diclofenac
Relexxii (methylphenidate)

+

diclofenac

1 interaction

Monitor/Modify Tx

methylphenidate + diclofenac

monitor BP: combo may incr. risk of HTN (additive effects)

• diclofenac topical
Relexxii (methylphenidate)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

methylphenidate + diclofenac topical

monitor BP: combo may incr. risk of HTN (additive effects)

• dicyclomine
Relexxii (methylphenidate)

+

dicyclomine

1 interaction

Monitor/Modify Tx

methylphenidate + dicyclomine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• diethylpropion
Relexxii (methylphenidate)

+

diethylpropion

1 interaction

Monitor/Modify Tx

methylphenidate + diethylpropion

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• diflunisal
Relexxii (methylphenidate)

+

diflunisal

1 interaction

Monitor/Modify Tx

methylphenidate + diflunisal

monitor BP: combo may incr. risk of HTN (additive effects)

• dihydroergotamine
Relexxii (methylphenidate)

+

dihydroergotamine

1 interaction

Monitor/Modify Tx

methylphenidate + dihydroergotamine

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of severe HTN, vasospasm, ischemia, serotonin syndrome (additive effects)

• diltiazem
Relexxii (methylphenidate)

+

diltiazem

1 interaction

Monitor/Modify Tx

methylphenidate + diltiazem

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• dobutamine
Relexxii (methylphenidate)

+

dobutamine

1 interaction

Monitor/Modify Tx

methylphenidate + dobutamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• dopamine
Relexxii (methylphenidate)

+

dopamine

1 interaction

Monitor/Modify Tx

methylphenidate + dopamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• doxapram
Relexxii (methylphenidate)

+

doxapram

1 interaction

Monitor/Modify Tx

methylphenidate + doxapram

monitor BP: combo may incr. risk of HTN (additive effects)

• doxazosin
Relexxii (methylphenidate)

+

doxazosin

1 interaction

Monitor/Modify Tx

methylphenidate + doxazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• doxepin
Relexxii (methylphenidate)

+

doxepin

1 interaction

Monitor/Modify Tx

methylphenidate + doxepin

monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. doxepin levels, risk of HTN, tachycardia, serotonin syndrome, CNS stimulatory effects, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• doxepin topical
Relexxii (methylphenidate)

+

doxepin topical

1 interaction

Monitor/Modify Tx

methylphenidate + doxepin topical

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• droxidopa
Relexxii (methylphenidate)

+

droxidopa

1 interaction

Monitor/Modify Tx

methylphenidate + droxidopa

monitor BP: combo may incr. risk of supine HTN (additive effects)

• eletriptan
Relexxii (methylphenidate)

+

eletriptan

1 interaction

Monitor/Modify Tx

methylphenidate + eletriptan

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, serotonin syndrome (additive effects)

• enalapril
Relexxii (methylphenidate)

+

enalapril

1 interaction

Monitor/Modify Tx

methylphenidate + enalapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• enalaprilat
Relexxii (methylphenidate)

+

enalaprilat

1 interaction

Monitor/Modify Tx

methylphenidate + enalaprilat

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• enzalutamide
Relexxii (methylphenidate)

+

enzalutamide

1 interaction

Monitor/Modify Tx

methylphenidate + enzalutamide

monitor BP: combo may incr. risk of HTN (additive effects)

• ephedrine injection
Relexxii (methylphenidate)

+

ephedrine injection

1 interaction

Monitor/Modify Tx

methylphenidate + ephedrine injection

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• ephedrine oral
Relexxii (methylphenidate)

+

ephedrine oral

1 interaction

Monitor/Modify Tx

methylphenidate + ephedrine oral

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• epinephrine
Relexxii (methylphenidate)

+

epinephrine

1 interaction

Monitor/Modify Tx

methylphenidate + epinephrine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• eplerenone
Relexxii (methylphenidate)

+

eplerenone

1 interaction

Monitor/Modify Tx

methylphenidate + eplerenone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• epoetin alfa
Relexxii (methylphenidate)

+

epoetin alfa

1 interaction

Monitor/Modify Tx

methylphenidate + epoetin alfa

monitor BP: combo may incr. risk of HTN (additive effects)

• erenumab
Relexxii (methylphenidate)

+

erenumab

1 interaction

Monitor/Modify Tx

methylphenidate + erenumab

monitor BP: combo may incr. risk of HTN (additive effects)

• ergotamine
Relexxii (methylphenidate)

+

ergotamine

1 interaction

Monitor/Modify Tx

methylphenidate + ergotamine

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of severe HTN, vasospasm, ischemia, serotonin syndrome (additive effects)

• esketamine
Relexxii (methylphenidate)

+

esketamine

1 interaction

Monitor/Modify Tx

methylphenidate + esketamine

monitor BP: combo may incr. risk of HTN (additive effects)

• esmolol
Relexxii (methylphenidate)

+

esmolol

1 interaction

Monitor/Modify Tx

methylphenidate + esmolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• estetrol (contraceptive)
Relexxii (methylphenidate)

+

estetrol (contraceptive)

1 interaction

Monitor/Modify Tx

methylphenidate + estetrol (contraceptive)

monitor BP: combo may incr. risk of HTN (additive effects)

• estradiol (contraceptive)
Relexxii (methylphenidate)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

methylphenidate + estradiol (contraceptive)

monitor BP: combo may incr. risk of HTN (additive effects)

• ethacrynic acid
Relexxii (methylphenidate)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

methylphenidate + ethacrynic acid

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ethinyl estradiol (contraceptive)
Relexxii (methylphenidate)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

methylphenidate + ethinyl estradiol (contraceptive)

monitor BP: combo may incr. risk of HTN (additive effects)

• etodolac
Relexxii (methylphenidate)

+

etodolac

1 interaction

Monitor/Modify Tx

methylphenidate + etodolac

monitor BP: combo may incr. risk of HTN (additive effects)

• etrasimod
Relexxii (methylphenidate)

+

etrasimod

1 interaction

Monitor/Modify Tx

methylphenidate + etrasimod

monitor BP: combo may incr. risk of HTN (additive effects)

• felodipine
Relexxii (methylphenidate)

+

felodipine

1 interaction

Monitor/Modify Tx

methylphenidate + felodipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fenfluramine
Relexxii (methylphenidate)

+

fenfluramine

1 interaction

Monitor/Modify Tx

methylphenidate + fenfluramine

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN (incl. hypertensive crisis), serotonin syndrome; may alter seizure control (additive effects; antagonistic effects, methylphenidate may decr. seizure threshold)

• fenoldopam
Relexxii (methylphenidate)

+

fenoldopam

1 interaction

Monitor/Modify Tx

methylphenidate + fenoldopam

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fenoprofen
Relexxii (methylphenidate)

+

fenoprofen

1 interaction

Monitor/Modify Tx

methylphenidate + fenoprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• fingolimod
Relexxii (methylphenidate)

+

fingolimod

1 interaction

Monitor/Modify Tx

methylphenidate + fingolimod

monitor BP: combo may incr. risk of HTN (additive effects)

• fludrocortisone
Relexxii (methylphenidate)

+

fludrocortisone

1 interaction

Monitor/Modify Tx

methylphenidate + fludrocortisone

monitor BP: combo may incr. risk of HTN (additive effects)

• flurbiprofen
Relexxii (methylphenidate)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

methylphenidate + flurbiprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• formoterol inhaled
Relexxii (methylphenidate)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

methylphenidate + formoterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• fosinopril
Relexxii (methylphenidate)

+

fosinopril

1 interaction

Monitor/Modify Tx

methylphenidate + fosinopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fosphenytoin
Relexxii (methylphenidate)

+

fosphenytoin

1 interaction

Monitor/Modify Tx

methylphenidate + fosphenytoin

monitor phenytoin levels: combo may incr. phenytoin levels, risk of toxicity; may alter seizure control (mechanism unknown, hepatic metab. possibly inhibited; antagonistic effects, methylphenidate may decr. seizure threshold)

• fostamatinib
Relexxii (methylphenidate)

+

fostamatinib

1 interaction

Monitor/Modify Tx

methylphenidate + fostamatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• frovatriptan
Relexxii (methylphenidate)

+

frovatriptan

1 interaction

Monitor/Modify Tx

methylphenidate + frovatriptan

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, serotonin syndrome (additive effects)

• fruquintinib
Relexxii (methylphenidate)

+

fruquintinib

1 interaction

Monitor/Modify Tx

methylphenidate + fruquintinib

monitor BP: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• glycopyrrolate
Relexxii (methylphenidate)

+

glycopyrrolate

1 interaction

Monitor/Modify Tx

methylphenidate + glycopyrrolate

monitor HR: combo may incr. risk of tachycardia (additive effects)

• guanfacine
Relexxii (methylphenidate)

+

guanfacine

1 interaction

Monitor/Modify Tx

methylphenidate + guanfacine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• hoodia
Relexxii (methylphenidate)

+

hoodia

1 interaction

Monitor/Modify Tx

methylphenidate + hoodia

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• hydralazine
Relexxii (methylphenidate)

+

hydralazine

1 interaction

Monitor/Modify Tx

methylphenidate + hydralazine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• hydrochlorothiazide
Relexxii (methylphenidate)

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

methylphenidate + hydrochlorothiazide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• hydrocortisone
Relexxii (methylphenidate)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

methylphenidate + hydrocortisone

monitor BP: combo may incr. risk of HTN (additive effects)

• hyoscyamine
Relexxii (methylphenidate)

+

hyoscyamine

1 interaction

Monitor/Modify Tx

methylphenidate + hyoscyamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• ibrutinib
Relexxii (methylphenidate)

+

ibrutinib

1 interaction

Monitor/Modify Tx

methylphenidate + ibrutinib

monitor BP: combo may incr. risk of HTN (additive effects)

• ibuprofen
Relexxii (methylphenidate)

+

ibuprofen

1 interaction

Monitor/Modify Tx

methylphenidate + ibuprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• indapamide
Relexxii (methylphenidate)

+

indapamide

1 interaction

Monitor/Modify Tx

methylphenidate + indapamide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• indomethacin
Relexxii (methylphenidate)

+

indomethacin

1 interaction

Monitor/Modify Tx

methylphenidate + indomethacin

monitor BP: combo may incr. risk of HTN (additive effects)

• iohexol
Relexxii (methylphenidate)

+

iohexol

1 interaction

Monitor/Modify Tx

methylphenidate + iohexol

if intrathecal iohexol use, D/C methylphenidate at least 48h before myelography, may resume at least 24h after procedure: combo may incr. risk of seizures (additive effects)

• iopamidol
Relexxii (methylphenidate)

+

iopamidol

1 interaction

Monitor/Modify Tx

methylphenidate + iopamidol

caution advised if intrathecal iopamidol use; consider holding methylphenidate at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• irbesartan
Relexxii (methylphenidate)

+

irbesartan

1 interaction

Monitor/Modify Tx

methylphenidate + irbesartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• isoflurane
Relexxii (methylphenidate)

+

isoflurane

1 interaction

Monitor/Modify Tx

methylphenidate + isoflurane

D/C methylphenidate day of surgery: combo may incr. risk of intraoperative HTN, tachycardia (mechanism unknown)

• isoproterenol
Relexxii (methylphenidate)

+

isoproterenol

1 interaction

Monitor/Modify Tx

methylphenidate + isoproterenol

monitor HR: combo may incr. risk of tachycardia (additive effects)

• isradipine
Relexxii (methylphenidate)

+

isradipine

1 interaction

Monitor/Modify Tx

methylphenidate + isradipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ketamine
Relexxii (methylphenidate)

+

ketamine

1 interaction

Monitor/Modify Tx

methylphenidate + ketamine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other sympathomimetic adverse effects (additive effects)

• ketoprofen
Relexxii (methylphenidate)

+

ketoprofen

1 interaction

Monitor/Modify Tx

methylphenidate + ketoprofen

monitor BP: combo may incr. risk of HTN (additive effects)

• ketorolac
Relexxii (methylphenidate)

+

ketorolac

1 interaction

Monitor/Modify Tx

methylphenidate + ketorolac

monitor BP: combo may incr. risk of HTN (additive effects)

• labetalol
Relexxii (methylphenidate)

+

labetalol

1 interaction

Monitor/Modify Tx

methylphenidate + labetalol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lanreotide
Relexxii (methylphenidate)

+

lanreotide

1 interaction

Monitor/Modify Tx

methylphenidate + lanreotide

monitor BP: combo may incr. risk of HTN (additive effects)

• lasmiditan
Relexxii (methylphenidate)

+

lasmiditan

1 interaction

Monitor/Modify Tx

methylphenidate + lasmiditan

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• leflunomide
Relexxii (methylphenidate)

+

leflunomide

1 interaction

Monitor/Modify Tx

methylphenidate + leflunomide

monitor BP: combo may incr. risk of HTN (additive effects)

• lenvatinib
Relexxii (methylphenidate)

+

lenvatinib

1 interaction

Monitor/Modify Tx

methylphenidate + lenvatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• levalbuterol inhaled
Relexxii (methylphenidate)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

methylphenidate + levalbuterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• levothyroxine
Relexxii (methylphenidate)

+

levothyroxine

1 interaction

Monitor/Modify Tx

methylphenidate + levothyroxine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• licorice
Relexxii (methylphenidate)

+

licorice

1 interaction

Monitor/Modify Tx

methylphenidate + licorice

monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects)

• lifileucel
Relexxii (methylphenidate)

+

lifileucel

1 interaction

Monitor/Modify Tx

methylphenidate + lifileucel

monitor HR: combo may incr. risk of tachycardia (additive effects)

• liothyronine
Relexxii (methylphenidate)

+

liothyronine

1 interaction

Monitor/Modify Tx

methylphenidate + liothyronine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• lisinopril
Relexxii (methylphenidate)

+

lisinopril

1 interaction

Monitor/Modify Tx

methylphenidate + lisinopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lorlatinib
Relexxii (methylphenidate)

+

lorlatinib

1 interaction

Monitor/Modify Tx

methylphenidate + lorlatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• losartan
Relexxii (methylphenidate)

+

losartan

1 interaction

Monitor/Modify Tx

methylphenidate + losartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lumacaftor/ivacaftor
Relexxii (methylphenidate)

+

lumacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

methylphenidate + lumacaftor/ ivacaftor

monitor BP: combo may incr. risk of HTN (additive effects)

• luspatercept
Relexxii (methylphenidate)

+

luspatercept

1 interaction

Monitor/Modify Tx

methylphenidate + luspatercept

monitor BP: combo may incr. risk of HTN (additive effects)

• magnesium salicylate
Relexxii (methylphenidate)

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

methylphenidate + magnesium salicylate

monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

• meclofenamate
Relexxii (methylphenidate)

+

meclofenamate

1 interaction

Monitor/Modify Tx

methylphenidate + meclofenamate

monitor BP: combo may incr. risk of HTN (additive effects)

• mefenamic acid
Relexxii (methylphenidate)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

methylphenidate + mefenamic acid

monitor BP: combo may incr. risk of HTN (additive effects)

• meloxicam
Relexxii (methylphenidate)

+

meloxicam

1 interaction

Monitor/Modify Tx

methylphenidate + meloxicam

monitor BP: combo may incr. risk of HTN (additive effects)

• methoxy polyethylene glycol-epoetin beta
Relexxii (methylphenidate)

+

methoxy polyethylene glycol-epoetin beta

1 interaction

Monitor/Modify Tx

methylphenidate + methoxy polyethylene glycol-epoetin beta

monitor BP: combo may incr. risk of HTN (additive effects)

• methscopolamine
Relexxii (methylphenidate)

+

methscopolamine

1 interaction

Monitor/Modify Tx

methylphenidate + methscopolamine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• methyldopa
Relexxii (methylphenidate)

+

methyldopa

1 interaction

Monitor/Modify Tx

methylphenidate + methyldopa

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• methylergonovine
Relexxii (methylphenidate)

+

methylergonovine

1 interaction

Monitor/Modify Tx

methylphenidate + methylergonovine

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of severe HTN, vasospasm, ischemia, serotonin syndrome (additive effects)

• methylprednisolone
Relexxii (methylphenidate)

+

methylprednisolone

1 interaction

Monitor/Modify Tx

methylphenidate + methylprednisolone

monitor BP: combo may incr. risk of HTN (additive effects)

• metoclopramide
Relexxii (methylphenidate)

+

metoclopramide

1 interaction

Monitor/Modify Tx

methylphenidate + metoclopramide

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome, HTN (additive effects)

• metolazone
Relexxii (methylphenidate)

+

metolazone

1 interaction

Monitor/Modify Tx

methylphenidate + metolazone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• metoprolol
Relexxii (methylphenidate)

+

metoprolol

1 interaction

Monitor/Modify Tx

methylphenidate + metoprolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• minoxidil
Relexxii (methylphenidate)

+

minoxidil

1 interaction

Monitor/Modify Tx

methylphenidate + minoxidil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• mirabegron
Relexxii (methylphenidate)

+

mirabegron

1 interaction

Monitor/Modify Tx

methylphenidate + mirabegron

monitor BP: combo may incr. risk of HTN (additive effects)

• modafinil
Relexxii (methylphenidate)

+

modafinil

1 interaction

Monitor/Modify Tx

methylphenidate + modafinil

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• moexipril
Relexxii (methylphenidate)

+

moexipril

1 interaction

Monitor/Modify Tx

methylphenidate + moexipril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nabumetone
Relexxii (methylphenidate)

+

nabumetone

1 interaction

Monitor/Modify Tx

methylphenidate + nabumetone

monitor BP: combo may incr. risk of HTN (additive effects)

• nadolol
Relexxii (methylphenidate)

+

nadolol

1 interaction

Monitor/Modify Tx

methylphenidate + nadolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• naproxen
Relexxii (methylphenidate)

+

naproxen

1 interaction

Monitor/Modify Tx

methylphenidate + naproxen

monitor BP: combo may incr. risk of HTN (additive effects)

• naratriptan
Relexxii (methylphenidate)

+

naratriptan

1 interaction

Monitor/Modify Tx

methylphenidate + naratriptan

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, serotonin syndrome (additive effects)

• naxitamab
Relexxii (methylphenidate)

+

naxitamab

1 interaction

Monitor/Modify Tx

methylphenidate + naxitamab

monitor BP: combo may incr. risk of HTN (additive effects)

• nebivolol
Relexxii (methylphenidate)

+

nebivolol

1 interaction

Monitor/Modify Tx

methylphenidate + nebivolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nefazodone
Relexxii (methylphenidate)

+

nefazodone

1 interaction

Monitor/Modify Tx

methylphenidate + nefazodone

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• nicardipine
Relexxii (methylphenidate)

+

nicardipine

1 interaction

Monitor/Modify Tx

methylphenidate + nicardipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nifedipine
Relexxii (methylphenidate)

+

nifedipine

1 interaction

Monitor/Modify Tx

methylphenidate + nifedipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nimodipine
Relexxii (methylphenidate)

+

nimodipine

1 interaction

Monitor/Modify Tx

methylphenidate + nimodipine

monitor BP: combo may decr. nimodipine efficacy (antagonistic effects)

• niraparib
Relexxii (methylphenidate)

+

niraparib

1 interaction

Monitor/Modify Tx

methylphenidate + niraparib

monitor BP: combo may incr. risk of HTN (additive effects)

• nisoldipine
Relexxii (methylphenidate)

+

nisoldipine

1 interaction

Monitor/Modify Tx

methylphenidate + nisoldipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• norepinephrine
Relexxii (methylphenidate)

+

norepinephrine

1 interaction

Monitor/Modify Tx

methylphenidate + norepinephrine

monitor BP: combo may incr. risk of severe HTN (additive effects)

• olmesartan medoxomil
Relexxii (methylphenidate)

+

olmesartan medoxomil

1 interaction

Monitor/Modify Tx

methylphenidate + olmesartan medoxomil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• olodaterol inhaled
Relexxii (methylphenidate)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

methylphenidate + olodaterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• orphenadrine
Relexxii (methylphenidate)

+

orphenadrine

1 interaction

Monitor/Modify Tx

methylphenidate + orphenadrine

monitor HR: combo may incr. risk of tachycardia (additive effects)

• osilodrostat
Relexxii (methylphenidate)

+

osilodrostat

1 interaction

Monitor/Modify Tx

methylphenidate + osilodrostat

monitor BP: combo may incr. risk of HTN (additive effects)

• oxaprozin
Relexxii (methylphenidate)

+

oxaprozin

1 interaction

Monitor/Modify Tx

methylphenidate + oxaprozin

monitor BP: combo may incr. risk of HTN (additive effects)

• oxymetazoline nasal
Relexxii (methylphenidate)

+

oxymetazoline nasal

1 interaction

Monitor/Modify Tx

methylphenidate + oxymetazoline nasal

monitor BP: combo may incr. risk of HTN (additive effects)

• oxytocin
Relexxii (methylphenidate)

+

oxytocin

1 interaction

Monitor/Modify Tx

methylphenidate + oxytocin

monitor BP: combo may incr. risk of HTN, incl. life-threatening (additive effects)

• ozanimod
Relexxii (methylphenidate)

+

ozanimod

1 interaction

Monitor/Modify Tx

methylphenidate + ozanimod

monitor BP: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• palonosetron
Relexxii (methylphenidate)

+

palonosetron

1 interaction

Monitor/Modify Tx

methylphenidate + palonosetron

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• pazopanib
Relexxii (methylphenidate)

+

pazopanib

1 interaction

Monitor/Modify Tx

methylphenidate + pazopanib

monitor BP: combo may incr. risk of HTN (additive effects)

• perindopril
Relexxii (methylphenidate)

+

perindopril

1 interaction

Monitor/Modify Tx

methylphenidate + perindopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• pexidartinib
Relexxii (methylphenidate)

+

pexidartinib

1 interaction

Monitor/Modify Tx

methylphenidate + pexidartinib

monitor BP: combo may incr. risk of HTN (additive effects)

• phenoxybenzamine
Relexxii (methylphenidate)

+

phenoxybenzamine

1 interaction

Monitor/Modify Tx

methylphenidate + phenoxybenzamine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• phentermine
Relexxii (methylphenidate)

+

phentermine

1 interaction

Monitor/Modify Tx

methylphenidate + phentermine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, CNS stimulatory effects (additive effects)

• phentolamine
Relexxii (methylphenidate)

+

phentolamine

1 interaction

Monitor/Modify Tx

methylphenidate + phentolamine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• phenylephrine
Relexxii (methylphenidate)

+

phenylephrine

1 interaction

Monitor/Modify Tx

methylphenidate + phenylephrine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular and CNS stimulatory effects (additive effects)

• phenylephrine injection
Relexxii (methylphenidate)

+

phenylephrine injection

1 interaction

Monitor/Modify Tx

methylphenidate + phenylephrine injection

monitor BP: combo may incr. risk of HTN (additive effects)

• phenylephrine nasal
Relexxii (methylphenidate)

+

phenylephrine nasal

1 interaction

Monitor/Modify Tx

methylphenidate + phenylephrine nasal

monitor BP: combo may incr. risk of HTN, other cardiovascular and CNS stimulatory effects (additive effects)

• phenylephrine ophthalmic
Relexxii (methylphenidate)

+

phenylephrine ophthalmic

1 interaction

Monitor/Modify Tx

methylphenidate + phenylephrine ophthalmic

monitor BP, HR; risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN, tachycardia (additive effects)

• phenylephrine rectal
Relexxii (methylphenidate)

+

phenylephrine rectal

1 interaction

Monitor/Modify Tx

methylphenidate + phenylephrine rectal

monitor BP: combo may incr. risk of HTN, other cardiovascular and CNS stimulatory effects (additive effects)

• phenytoin
Relexxii (methylphenidate)

+

phenytoin

1 interaction

Monitor/Modify Tx

methylphenidate + phenytoin

monitor phenytoin levels: combo may incr. phenytoin levels, risk of toxicity; may alter seizure control (mechanism unknown, hepatic metab. possibly inhibited; antagonistic effects, methylphenidate may decr. seizure threshold)

• pindolol
Relexxii (methylphenidate)

+

pindolol

1 interaction

Monitor/Modify Tx

methylphenidate + pindolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• piroxicam
Relexxii (methylphenidate)

+

piroxicam

1 interaction

Monitor/Modify Tx

methylphenidate + piroxicam

monitor BP: combo may incr. risk of HTN (additive effects)

• ponatinib
Relexxii (methylphenidate)

+

ponatinib

1 interaction

Monitor/Modify Tx

methylphenidate + ponatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• ponesimod
Relexxii (methylphenidate)

+

ponesimod

1 interaction

Monitor/Modify Tx

methylphenidate + ponesimod

monitor BP: combo may incr. risk of HTN (additive effects)

• pralsetinib
Relexxii (methylphenidate)

+

pralsetinib

1 interaction

Monitor/Modify Tx

methylphenidate + pralsetinib

monitor BP: combo may incr. risk of HTN (additive effects)

• prazosin
Relexxii (methylphenidate)

+

prazosin

1 interaction

Monitor/Modify Tx

methylphenidate + prazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• prednisolone
Relexxii (methylphenidate)

+

prednisolone

1 interaction

Monitor/Modify Tx

methylphenidate + prednisolone

monitor BP: combo may incr. risk of HTN (additive effects)

• prednisone
Relexxii (methylphenidate)

+

prednisone

1 interaction

Monitor/Modify Tx

methylphenidate + prednisone

monitor BP: combo may incr. risk of HTN (additive effects)

• primidone
Relexxii (methylphenidate)

+

primidone

1 interaction

Monitor/Modify Tx

methylphenidate + primidone

monitor primidone levels; caution advised if seizure disorder use: combo may incr. primidone levels, risk of toxicity; may alter seizure control (mechanism unknown, hepatic metab. possibly inhibited; antagonistic effects, methylphenidate may decr. seizure threshold)

• propranolol
Relexxii (methylphenidate)

+

propranolol

1 interaction

Monitor/Modify Tx

methylphenidate + propranolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• protriptyline
Relexxii (methylphenidate)

+

protriptyline

1 interaction

Monitor/Modify Tx

methylphenidate + protriptyline

monitor BP, HR, serotonin syndrome sx, especially during initiation/titration: combo may incr. protriptyline levels, risk of HTN, tachycardia, serotonin syndrome, other adverse effects (mechanism unknown, hepatic metab. possibly inhibited, additive effects)

• pseudoephedrine
Relexxii (methylphenidate)

+

pseudoephedrine

1 interaction

Monitor/Modify Tx

methylphenidate + pseudoephedrine

monitor BP, HR: combo may incr. risk of HTN, tachycardia, CNS stimulatory effects (additive effects)

• quetiapine
Relexxii (methylphenidate)

+

quetiapine

1 interaction

Monitor/Modify Tx

methylphenidate + quetiapine

monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

• quinapril
Relexxii (methylphenidate)

+

quinapril

1 interaction

Monitor/Modify Tx

methylphenidate + quinapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ramipril
Relexxii (methylphenidate)

+

ramipril

1 interaction

Monitor/Modify Tx

methylphenidate + ramipril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ramucirumab
Relexxii (methylphenidate)

+

ramucirumab

1 interaction

Monitor/Modify Tx

methylphenidate + ramucirumab

monitor BP: combo may incr. risk of HTN (additive effects)

• regorafenib
Relexxii (methylphenidate)

+

regorafenib

1 interaction

Monitor/Modify Tx

methylphenidate + regorafenib

monitor BP: combo may incr. risk of HTN (additive effects)

• ripretinib
Relexxii (methylphenidate)

+

ripretinib

1 interaction

Monitor/Modify Tx

methylphenidate + ripretinib

monitor BP: combo may incr. risk of HTN (additive effects)

• rizatriptan
Relexxii (methylphenidate)

+

rizatriptan

1 interaction

Monitor/Modify Tx

methylphenidate + rizatriptan

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, serotonin syndrome (additive effects)

• ropinirole
Relexxii (methylphenidate)

+

ropinirole

1 interaction

Monitor/Modify Tx

methylphenidate + ropinirole

monitor BP: combo may incr. risk of HTN (additive effects)

• rotigotine transdermal
Relexxii (methylphenidate)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

methylphenidate + rotigotine transdermal

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• salmeterol inhaled
Relexxii (methylphenidate)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

methylphenidate + salmeterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• salsalate
Relexxii (methylphenidate)

+

salsalate

1 interaction

Monitor/Modify Tx

methylphenidate + salsalate

monitor BP w/ high-dose salsalate: combo may incr. risk of HTN (additive effects)

• SAMe
Relexxii (methylphenidate)

+

SAMe

1 interaction

Monitor/Modify Tx

methylphenidate + SAMe

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• selpercatinib
Relexxii (methylphenidate)

+

selpercatinib

1 interaction

Monitor/Modify Tx

methylphenidate + selpercatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• sevoflurane
Relexxii (methylphenidate)

+

sevoflurane

1 interaction

Monitor/Modify Tx

methylphenidate + sevoflurane

D/C methylphenidate day of surgery: combo may incr. risk of intraoperative HTN, tachycardia (mechanism unknown)

• siponimod
Relexxii (methylphenidate)

+

siponimod

1 interaction

Monitor/Modify Tx

methylphenidate + siponimod

monitor BP: combo may incr. risk of HTN (additive effects)

• solriamfetol
Relexxii (methylphenidate)

+

solriamfetol

1 interaction

Monitor/Modify Tx

methylphenidate + solriamfetol

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• sorafenib
Relexxii (methylphenidate)

+

sorafenib

1 interaction

Monitor/Modify Tx

methylphenidate + sorafenib

monitor BP: combo may incr. risk of HTN (additive effects)

• spironolactone
Relexxii (methylphenidate)

+

spironolactone

1 interaction

Monitor/Modify Tx

methylphenidate + spironolactone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• St. John's wort
Relexxii (methylphenidate)

+

St. John's wort

1 interaction

Monitor/Modify Tx

methylphenidate + St. John's wort

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome; may decr. methylphenidate efficacy (additive effects; mechanism unknown)

• sulindac
Relexxii (methylphenidate)

+

sulindac

1 interaction

Monitor/Modify Tx

methylphenidate + sulindac

monitor BP: combo may incr. risk of HTN (additive effects)

• sumatriptan
Relexxii (methylphenidate)

+

sumatriptan

1 interaction

Monitor/Modify Tx

methylphenidate + sumatriptan

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, serotonin syndrome (additive effects)

• sunitinib
Relexxii (methylphenidate)

+

sunitinib

1 interaction

Monitor/Modify Tx

methylphenidate + sunitinib

monitor BP: combo may incr. risk of HTN (additive effects)

• tacrolimus
Relexxii (methylphenidate)

+

tacrolimus

1 interaction

Monitor/Modify Tx

methylphenidate + tacrolimus

monitor BP: combo may incr. risk of HTN (additive effects)

• tagraxofusp
Relexxii (methylphenidate)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

methylphenidate + tagraxofusp

monitor BP: combo may incr. risk of HTN (additive effects)

• telmisartan
Relexxii (methylphenidate)

+

telmisartan

1 interaction

Monitor/Modify Tx

methylphenidate + telmisartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• terazosin
Relexxii (methylphenidate)

+

terazosin

1 interaction

Monitor/Modify Tx

methylphenidate + terazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• terbutaline
Relexxii (methylphenidate)

+

terbutaline

1 interaction

Monitor/Modify Tx

methylphenidate + terbutaline

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• teriflunomide
Relexxii (methylphenidate)

+

teriflunomide

1 interaction

Monitor/Modify Tx

methylphenidate + teriflunomide

monitor BP: combo may incr. risk of HTN (additive effects)

• testosterone
Relexxii (methylphenidate)

+

testosterone

1 interaction

Monitor/Modify Tx

methylphenidate + testosterone

monitor BP: combo may incr. risk of HTN (additive effects)

• thyroid
Relexxii (methylphenidate)

+

thyroid

1 interaction

Monitor/Modify Tx

methylphenidate + thyroid

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• timolol
Relexxii (methylphenidate)

+

timolol

1 interaction

Monitor/Modify Tx

methylphenidate + timolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• tivozanib
Relexxii (methylphenidate)

+

tivozanib

1 interaction

Monitor/Modify Tx

methylphenidate + tivozanib

monitor BP: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• tolmetin
Relexxii (methylphenidate)

+

tolmetin

1 interaction

Monitor/Modify Tx

methylphenidate + tolmetin

monitor BP: combo may incr. risk of HTN (additive effects)

• torsemide
Relexxii (methylphenidate)

+

torsemide

1 interaction

Monitor/Modify Tx

methylphenidate + torsemide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• trametinib
Relexxii (methylphenidate)

+

trametinib

1 interaction

Monitor/Modify Tx

methylphenidate + trametinib

monitor BP: combo may incr. risk of HTN (additive effects)

• trandolapril
Relexxii (methylphenidate)

+

trandolapril

1 interaction

Monitor/Modify Tx

methylphenidate + trandolapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• trazodone
Relexxii (methylphenidate)

+

trazodone

1 interaction

Monitor/Modify Tx

methylphenidate + trazodone

monitor serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of serotonin syndrome (additive effects)

• triamcinolone
Relexxii (methylphenidate)

+

triamcinolone

1 interaction

Monitor/Modify Tx

methylphenidate + triamcinolone

monitor BP: combo may incr. risk of HTN (additive effects)

• triamterene
Relexxii (methylphenidate)

+

triamterene

1 interaction

Monitor/Modify Tx

methylphenidate + triamterene

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• trospium
Relexxii (methylphenidate)

+

trospium

1 interaction

Monitor/Modify Tx

methylphenidate + trospium

monitor HR: combo may incr. risk of tachycardia (additive effects)

• vadadustat
Relexxii (methylphenidate)

+

vadadustat

1 interaction

Monitor/Modify Tx

methylphenidate + vadadustat

monitor BP: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• valsartan
Relexxii (methylphenidate)

+

valsartan

1 interaction

Monitor/Modify Tx

methylphenidate + valsartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• vamorolone
Relexxii (methylphenidate)

+

vamorolone

1 interaction

Monitor/Modify Tx

methylphenidate + vamorolone

monitor BP: combo may incr. risk of HTN (additive effects)

• vandetanib
Relexxii (methylphenidate)

+

vandetanib

1 interaction

Monitor/Modify Tx

methylphenidate + vandetanib

monitor BP: combo may incr. risk of HTN (additive effects)

• vasopressin
Relexxii (methylphenidate)

+

vasopressin

1 interaction

Monitor/Modify Tx

methylphenidate + vasopressin

monitor BP: combo may incr. risk of HTN (additive effects)

• verapamil
Relexxii (methylphenidate)

+

verapamil

1 interaction

Monitor/Modify Tx

methylphenidate + verapamil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• vilanterol inhaled
Relexxii (methylphenidate)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

methylphenidate + vilanterol inhaled

monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

• viloxazine
Relexxii (methylphenidate)

+

viloxazine

1 interaction

Monitor/Modify Tx

methylphenidate + viloxazine

monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

• voclosporin
Relexxii (methylphenidate)

+

voclosporin

1 interaction

Monitor/Modify Tx

methylphenidate + voclosporin

monitor BP: combo may incr. risk of HTN (additive effects)

• warfarin
Relexxii (methylphenidate)

+

warfarin

1 interaction

Monitor/Modify Tx

methylphenidate + warfarin

monitor INR, bleeding s/sx: combo may incr. warfarin levels, risk of bleeding (incl. life-threatening), other adverse effects (mechanism unknown, hepatic metab. possibly inhibited)

• ziv-aflibercept
Relexxii (methylphenidate)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

methylphenidate + ziv-aflibercept

monitor BP: combo may incr. risk of HTN (additive effects)

• zolmitriptan
Relexxii (methylphenidate)

+

zolmitriptan

1 interaction

Monitor/Modify Tx

methylphenidate + zolmitriptan

monitor BP, serotonin syndrome sx, especially during initiation/titration: combo may incr. risk of HTN, serotonin syndrome (additive effects)